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Abstract 
Background: Cardiac and systemic hemodynamics have been historically  in the domain 
of invasive cardiology, but  recent advances in real-time 3-Dimensional echocardiography 
(RT3D echo) provide a reliable measurement of ventricular volumes, allowing to measure 
a set of hemodynamic parameters previously difficult or impossible to obtain with standard 
2D echo.   
Aim: To assess the feasibility of a comprehensive hemodynamic study with  RT-3D echo. 
Methods: We enrolled 136  patients referred for routine echocardiography : 44 normal (N), 
57 hypertensive (HYP), and 35 systolic heart failure  patients (HF).  All patients underwent 
standard 2D echo examination followed by RT3D echo examination, including 
measurement of left ventricular (LV) end-diastolic and end-systolic volumes and derived 
assessment of LV elastance (an index of LV contractility), arterial elastance (characterizing 
the aortic input impedance of the arterial system downstream of the aortic valve); 
ventricular-arterial coupling (a central determinant of net cardiovascular performance); 
systemic vascular resistances. Blood pressure was derived from cuff sphygmomanometer 
and heart rate from ECG. 
Results: A complete 2D echo was performed in all 136 patients. 3D echo examination was 
obtained in 130 patients (feasibility=95%). Standard 2D echo examination was completed 
in 14.8± 2.2 min. Acquisition of 3D images required an  average time of  5±0.9 min  (range 
3.5-7.5 min) and image analysis was completed in 10.1±2.8 min (range 6-12 min) per 
patient. Compared to N and HYP, HF patients showed reduced LV elastance (1.7±1.5 
mmHg mL-1m-2, p <0.001 vs N= 3.8±1.3 and HYP=3.8±1.3) and ventricular-arterial 
coupling (0.6±0.5, p<0.01 vs N=1.4±0.4 and HYP=1.2±0.4). Systemic vascular resistances 
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were highest in HYP (2736 ± 720, p< .01 vs N=1980 ± 432 and vs HF= 1855 ± 636 
dyne*s/cm5). The LV elastance was related to EF (r=0.73, p<0.01 ) and arterial pressure 
was moderately related to systemic vascular resistances (r= 0.54, p<0.01). The 
ventricular-arterial coupling was unrelated to systemic vascular resistances (r=-0.04, p 
NS).  
Conclusion: RT-3D echo allows a  non invasive, comprehensive assessment of cardiac 
and systemic hemodynamics, offering insight access to key variables – such as increased 
systemic vascular resistances in hypertensives and reduced ventricular-arterial coupling in 
heart failure patients . 
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List of abbreviations: 
 AE=Arterial Elastance  
ARBs=Angiotensin Receptor Blockers 
BSA=Body surface Area 
EaE=Effective arterial elastance  
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 ESP=End-Systolic Pressure 
 ESV=End-Systolic Volume  
 HF=Heart Failure  
 LV=Left Ventricular 
 MAP=Mean Arterial Pressure  
 SV= Stroke Volume 
 SVR=Systemic Vascular Resistance 
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Introduction.  
LV function, ventricular volumes, and ejection fraction are routinely assessed by standard 
2D echo for early detection of cardiac disease, to monitor disease progression and to 
assess response to treatment. Standard echocardiographic evaluation of hemodynamic 
parameters shows an acceptable correlation with invasive measurements in population 
studies. However, in the individual patient, the dispersion of values may be so wide to limit 
clinical applications, mostly due to intra- and inter-observer variability of  volumes 
measurements (1). Although 2 D echocardiographic measurements have acceptable 
degree of variability to be used in clinical practice even in patients with distorted left 
ventricles, RT-3D improves accuracy of non-invasive evaluation of cardiac volumes limiting 
data scatter and provides reliable clinical guidance (2).  Moreover RT-3D echo, by 
accurate assessment of stroke volume (SV), allows to derive a set of hemodynamic 
measures usually difficult or impossible to obtain with 2D echo, such as LV elastance, 
arterial elastance, ventricular-arterial coupling and systemic vascular resistances (3-5).  
The underlying idea of the present study was to take advantage of the superiority of 3D 
over 2D echocardiography in assessing LV volumes to derive more accurate non invasive 
estimates of cardiac-vascular function (6-7). 
The purpose of this study was to evaluate the feasibility and time cost  of RT-3D echo,  as 
compared to standard 2D echo,  in the setting of a primary care echocardiography 
laboratory. 
We also evaluated RT3D derived cardiac and vascular hemodynamics in hypertensive and 
heart failure patients. In fact, RT3D-derived parameters such as left ventricular elastance 
or systemic vascular resistances reflect the complex interactions between the heart and its 
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internal and external loads and are of emerging importance in the assessment and 
management of hypertension and heart failure (8). 
 
Study population 
The study has been conducted in 3 different primary care cardiology outpatients clinic 
(Echocardiography Laboratories of Savona, of Lucca, and of Barga cardiology services). 
All exams were performed by the same cardiologist-echocardiographer who performed 
both 2D and 3D echo examinations .  To minimize variability the same observed, acquired 
and analyzed all studies. The observer had undergone a dedicated 9 month training on 3-
D and the variability observed in a consecutive set of 10 studies was consistently < 10% 
for LV volumes. We initially considered 400 patients, referred for clinically driven Echo 
evaluation between  May  2009 and  June 2011. Sixty patients denied the consent to enter 
the 3D part of the study, 50 had technically difficult 2D-Echo examination; 154 had 
exclusion criteria conditions (such as previous myocardial infarction, valvular heart 
disease, patients younger than 40 y or older than 79 y). One hundred and thirty six  
patients were eventually included in the study. They complied with  the inclusion criteria: 
1. Sinus Rhythm; 
2.  Willingness to enter the  study; 
3.  Technically good 2D echo study;  
4. Clinical-echocardiographic diagnosis of  no structural heart disease (N, with SBP≤ 139 
mmHg, diastolic blood pressure ≤ 85 mmHg , and a BMI≤ 30 Kg/m2), free from major 
coronary risk factors, including diabetes, hypercholesterolemia, and cigarette smoking; 
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5. Clinical-echocardiographic  diagnosis of essential   hypertension (HYP), previously 
made according to standard criteria (9): history of long standing high blood pressure, 
under active treatment) with EF>50% ; 
6. Clinical-echocardiographic diagnosis  of heart failure (HF), history of  dyspnea on 
effort, under active treatment, with EF<40%.  
Study protocol 
Following standard 2D echo examination, patients underwent RT-3D echo with 
measurement of raw data of  LV EDV and ESV  and derived assessment of (10): LV 
elastance (an index of LV contractility); arterial elastance (AE) (characterizing the aortic 
input impedance of the arterial system downstream of the aortic valve); ventricular-arterial 
coupling (a central determinant of net cardiovascular performance); systemic vascular 
resistances (SVR). Blood pressure was derived from cuff sphygmomanometer and heart 
rate from 1- lead ECG (on echo monitor). The medical records of all included patients were 
reviewed in detail by one investigator to identify N, HYP and HF patients. For all patients, 
age, cuff blood pressure, height, weight, body mass index (BMI) and body surface area 
(BSA) were calculated and recorded. 
Mean arterial pressure (MAP) was calculated as diastolic blood pressure + (systolic blood 
pressure  - diastolic blood pressure/3). Mitral regurgitation and pulmonary arterial pressure 
were estimated from standard 2D echo. Forty four patients with no overt cardiac disease, a 
SBP ≤ 139 mmHg, and a BMI ≤ 30 Kg/m2, constituted the N group. Fifty seven subjects 
with hypertension but no HF constituted the HTN group. Thirty five patients with a clinical 
diagnosis of heart failure and EF below 40% constituted the systolic HF group. 
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Methods 
Two-dimensional echocardiography. 
Standard 2-dimensional echocardiography was performed according to the 
recommendation of the European Association of Echocardiography (5) using a Philips I33 
scanner (Andover, Mass) equipped with a phased array S5-1  1.3-3.6 MHz probe with 
second harmonic capability. Left atrial dimensions (parasternal and 4 chambers view), LV 
end-diastolic volumes (EDV) and end-systolic volumes (ESV) were measured. Ejection 
fraction (EF), stroke volume (SV), and cardiac output (CO) were calculated according to 
standard formula (5).  
Three-dimensional echocardiography. 
Real time 3-dimensional echocardiography images were recorded with a Philips I33 
equipped with a X3-1 1-3 MHz matrix –phased array transducer in a 60 x70 pyramid 
shaped volume containing the entire left ventricle. Volumetric data were obtained only from 
the apical window and displayed as conventional 2D apical which were digitalized with 
final interpretation made off –line with manual identification of chambers contours in 
selected image. Four cardiac cycles were stitched together to obtain LV volumes. 
 3D-images were obtained soon after completing the 2D study using the same 
echocardiographic machines with a fast switch between the 2 probes (4). 
BP and HR were taken simultaneously during volume assessment, from cuff 
sphigmomanometry and from EKG, respectively. 
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Data acquisition 
LV EDV and ESV were measured from apical four- and two-chamber view, using the 
biplane Simpson-method (5). Only representative cycles with optimal endocardial 
visualization were measured and the average of three measurements was taken. The 
endocardial border was traced, excluding the papillary muscles. The frame captured at the 
R wave of the ECG was considered to be the end-diastolic frame, and the frame with the 
smallest left ventricular cavity the end systolic frame . 
Inter-observer variability was available in a subset of 10 consecutive studies analyzed by 2 
separate observers (MCS and AG). 
 
Arterial elastance and ventricular-arterial coupling 
Ventricular arterial coupling was derived by the ratio of LV systolic elastance  (systolic 
pressure/ end-systolic volume) to arterial elastance (ratio of end-systolic pressure by 
stroke volume). Effective arterial elastance (EaE), characterizing the aortic input 
impedance of the arterial system downstream of the aortic valve, was estimated as end-
systolic pressure (ESP) divided by stroke volume (SV) and expressed as SP/ESV 
index=mmHg/mL/m2. ESP was estimated as systolic pressure times 0.9 (7). Because 
stroke volume (and input impedance) varies directly with body size, arterial elastance was 
corrected for BSA (EaE) to better reflect differences in arterial properties with age and 
between the genders adjusted for differences in body size (11). Of note ventricular-arterial 
coupling is ventricular elastance/arterial elastance, which can further be described as: 
ESP/ESV divided by ESP/SV: the pressure terms in the numerator and the denominator 
cancel out, and ventricular-arterial coupling equals to stroke volume/end-systolic volume. 
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Systemic Vascular Resistance (SVR) 
SVR were calculated according to the traditional formula: 
SVR = 80 * (MAP-5)/CO, 
where 5 is an approximation of the right atrial pressure and MAP is mean arterial pressure. 
Systemic arterial compliance 
Systemic arterial compliance  was calculated as SV index/systemic arterial pulse pressure; 
where pulse pressure = SBP - DBP (10,12). 
 
 
Statistics  
Software (SPSS 11 for Windows, SPSS, Chicago, Ill) was used for statistical analysis. The 
statistical analyses included descriptive statistics (frequency and percentage of categorical 
variables and mean and standard deviation of continuous variables). One-way ANOVA 
was used to compare continuous variables between groups with intergroup comparisons 
by Newman-Keuls test. The agreement between continuous or discrete data was tested by 
the Bland-Altman method and by the concordance  correlation coefficient comparing the 
mean differences between the two methods of measurements and 95% limits of 
agreement as the mean difference. A coefficient of variation was calculated to assess 
inter-observer  variability. 
A p value of  0.05 was considered as statistically significant. 
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RESULTS 
Patients demographic and hemodynamic parameters are presented in Table 1.  
The 57 HYP patients were under-treatment  with ACE-inhibitors (68%), and/or diuretics 
(84%), and/or ARBs (36%), and/or Ca-channel blockers (25%). The 35 HF patients were 
under-treatment with ACE-inhibitors (86%), and/or diuretics (78%), and/or ARBs  (28%), 
and/or β-blockers (68%). Standard 2D Echo was performed in 136 (68 females) patients. 
Diagnostic quality images with RT-3D echo  were obtained in 130 patients (feasibility 95%) 
that were distributed as follows: no structural cardiac disease (N, 44), hypertension without 
heart failure (HTN, 56), and systolic heart failure   (EF<40%) (HF, 30). The commonest 
reason for incomplete RT3D was  ventricular dimension exceeding the area covered by the 
probe.  The feasibility  of RT-3D was 130/136 (95 %)  when referred to the population of 
136 patients evaluated with this technique (which had, by selection, good 2D echo 
images); however, if the initial population of 186 patients screened by 2D echo with clinical 
and echocardiographic eligibility criteria is considered, the overall feasibility falls to 
130/186 (70 %), since patients with 2D echo images invariably have poor 3D images. 
LV volumes obtained with standard 2D-echo and with RT-3D echo were plotted according 
to the Bland-Altman method, assuming 3D- echo as the minuend, and 2D echo as the 
subtracting element. End-systolic as well end-diastolic volumes showed a significant 
agreement (p<0.001,Fig. 1-2). In particular, a mean difference of 5.6 ml (95% CI 1.8-9.4; 
r=1.52; p=0.28) for ESV and 6.1 ml (95% CI 5.6-6.8; r=0.21; p=0.12) for EDV was found, 
implying a slight volume overestimation by 3D (or , more likely, underestimation by 2D). 
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The coefficient of variation between 2 observers for LVESV and LVEDV was 4 % and 8 %  
respectively. 
 
 
Additional workload associated with RT3D echo. 
Standard 2D echo examination was completed in 14.8± 2.2 min. Acquisition of 3D images 
required an additional time of   5±0.9 min  (range 3.5min/7.5min) and image analysis was 
completed in 10±2.8 min (range 6.6 min-12.8 min) per patient. Therefore the completion of 
a RT3D echo study from imaging to analysis requires a time interval comparable to a 
standard 2D examination . 
Non-invasive hemodynamic assessment  
A reduced ventricular elastance was found in HF patients as compared to N and HYP  
(Table 2 and Fig.3). Ventricular-arterial coupling was also reduced in HF patients 
compared to N and HYP (Table 2 and Fig.4). Vascular elastance was significantly higher 
in HYP  than in N and HF patients (Table 2 and Fig.5). HYP had the highest systemic 
vascular resistances (Table 2 and Fig.6). 
A significant relation was found between LV elastance and EF (r=0.73, p<0.01), not 
surprisingly, since this is an auto-correlation (Fig.7, panel A) and arterial pressure was 
moderately related to systemic vascular resistance (r=0.54, p<0.01) (Fig.7, panel B). No 
significant correlation was found between ventricular-arterial coupling and systemic 
vascular resistances (r=0.04, p=NS) .  
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Discussion 
The primary purpose of this study was to test  the feasibility of RT3D, and to estimate the 
time required to complete a RT-3D examination as compared to standard echo. The main 
finding of this study is that RT3D Echo, thanks to recent technological advances and to 
new, user-friendly software (10), can be performed in most patients referred for routine 
echo examination, and  that RT-3D echo allows the assessment of cardiac hemodynamics 
in   a variety of clinical conditions, in a relatively easy and quick fashion, at an acceptable 
time cost.  Of interest, diagnostic quality RT-3D images were obtained in 95% of patients 
with an acceptable acoustic window. The commonest reason for failed RT3D examination 
in this group was the presence of a markedly dilated left ventricle, exceeding the field of 
view of the 3D probe. Further technological advances promise to  overcome this limitation. 
Anticipated technological advances and new softwares will  further shorten both 
acquisition time and analysis time, rendering RT-3D echo more and more  attractive. 
In keeping with previous studies, we found that LV elastance, vascular elastance, 
ventricular-arterial coupling, systemic vascular resistance, and other key hemodynamic 
parameters such as CO and SV, can be easily and quickly obtained with RT-3D echo in a 
number of cardiac conditions, including HYP, HF, and N patients (10-12). 
3D echo makes it possible to capture the shape and function of the entire LV in a single 
data set. Compared with 2D echo, this is an advantage for LV quantification, since 
geometric assumptions of LV shape can be ignored. Moreover, 3D echo allows for 
manually aligning the displayed view to the true anatomical LV main axis, avoiding 
foreshortening and ensuing a precise identification of the LV apex.  
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In direct comparisons, RT-3D echo has been shown to be as accurate as contrast-
enhanced 2D echo in left ventricular volume measurement. In addition, LV and RV 
volumes by 3D Echo have been reported to compare favorably with cardiac magnetic 
resonance (CMR) and Gated-SPECT imaging (13-16). 
Compared to cardiac MRI, the currently accepted gold standard technique for LV 
quantification, 3D echo provides a good agreement for assessing EF with slightly 
underestimation of volumes, which may be attributed to the different modality in 
visualization of trabeculae and valves between the two techniques (17).  
Limitations 
This study was not aimed to assess accuracy and reproducibility of 3D echo measurement 
of LV volumes, but to investigate the additional time costs of RT-3D images and its 
practicability . We completed the study in a primary care setting , very different from an 
academic, research-oriented tertiary care hospital, and populated by real unselected 
patients evaluated by busy non hyper-specialized doctors. Yet also in this challenging 
setting the technique provided robust, reproducible and consistent results, of potential 
clinical value. 
Calculation of the end-systolic pressure/volume ratio would require the measurement of LV 
pressure in end-systole. Because only non-invasive measurements were available, 
systolic cuff pressure was used as a surrogate for end-systolic pressure. This certainly 
introduces an approximation, however, there is a tight relationship between peak and end-
systolic pressure (18). 
The conceptual novelty of the employed approach is limited, since already Bombardini et 
al. extensively showed that this approach can be usefully applied to non invasive 
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ultrasound at rest and during stress such as exercise, dobutamine, dipyridamole and 
pacing (11,12,19). However, we adopted firstly 3D echo which may introduce a crucial 
step-up in the feasibility and accuracy of the method, allowing to avoid inherent 
inaccuracies of the 2D-approach for volume calculations.  
Hemodynamic variables assessed in this study may be affected by drug therapy. ß-
blockers may reduce aortic wave reflection and improve left ventricular /vascular coupling, 
and 68% of patients in the HF group were on ß-blockers (20). However, this observation 
does not impact on our conclusions because  we observed a reduced V/A coupling in the 
HF group as compared to N and HYP patients, so, if anything, we are underestimating  the 
difference.  
  
Conclusion 
In this study we have shown that RT-3D can be performed in the vast majority of patients 
referred for echocardiographic examination at an acceptable extra-time cost for additional 
imaging and analysis, compared to standard 2D echo. 
 
Only patients with bad acoustic window or with markedly enlarged left ventricle may pose 
a difficult challenge.  Reliable and detailed assessment of cardiac and systemic 
hemodynamics more than compensate for the time required for data acquisition and  off-
line analysis.  Standard 2D echo  will certainly remain  the first line technique for LV 
assessment in the near future, given its large availability, its relative easiness, and the 
established role. However, when volumes are important and sequential testing is required, 
the 3D technique appears to be an attractive and practical alternative, offering also insight 
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into variables of pathophysiological and potential clinical relevance, such as increased 
systemic vascular resistances in hypertensives and reduced left ventricular elastance in 
heart failure patients.  
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Legend to figures. 
Fig.1. Bland-Altman plot for End-systolic volumes 
Fig.2. Bland-Altman plot for End-diastolic volumes 
Fig.3. Ventricular elastance. 
Fig.4. Ventricular-arterial coupling 
Fig.5 Arterial Elastance  
Fig. 6 Systemic Vascular Resistances 
Fig. 7. Ventricular elastance vs ejection fraction (panel A) and Vascular elastance vs 
systolic pressure (Panel B)  
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Table 1. Study population and hemodynamic parameters 
  
    
 N HYP HF 
N. 44 57 35 
Females, (%)  73 39 40 
 
BSA m2 1.7 ±0.2 1.9±0.2 1.9±0.2 
LVEF%  62±6  63±9  35±5       * 
LVEDV (ml/m2) 51±14 50±13 83±28  * 
LVESV (ml/m2) 19±5  20±8 56±29   * 
SBP (mmHg) 127±15 147±14   * 126±18 
DBP (mmHg)    70±9
  
83±8     * 78±11 
 
 
  
• = p<.01 vs other groups 
All echo data are obtained with RT3D echocardiography 
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Table 2. Hemodynamic evaluation by RT3D echocardiography 
 
 N HYP Syst HF 
LV Elastance 
mmHg/ml/m2 
3.8±1.2 3.8±1.3 1.7±1.5           *      
Arterial Elastance 
mmHg/ml/m2 
2.7±0.9 3.3±0.9     * 2.4±0.8 
V-A Coupling 1.4±0.4 1.2±0.4 0.6±0.5           * 
SVR  
dyne*s/cm5 
1980±432 2736±720 *              1855±636 
 
 
  
* = p<.01 vs other groups 
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Fig.1. Bland-Altman plot for End-systolic volumes 
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Fig.2. Bland-Altman plot for End-diastolic volumes 
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Fig.3. Ventricular elastance 
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Fig.4. Ventricular-arterial coupling 
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Fig.5 Arterial Elastance  
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Fig. 6 Systemic Vascular Resistances 
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Fig. 7. Ventricular elastance vs ejection fraction (panel A) and Vascular elastance vs 
systolic pressure (Panel B)  
Units: EF:%, PAS mmHg, Ventricular elastance and Vascular elastance: mmHg/ml/m2 . 
 
 
 
 
